

PATENT ATTORNEY DOCKET NO. 00786/351006

Certificate of Mailing: Date of Deposit: April 23, 2007

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, Attention: Certificate of Correction Branch.

Sarah Wilcox

Printed name of person mailing correspondence

Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Ruvkun et al.

Confirmation No.: 2040

Serial No.:

09/963,693

Art Unit:

1633

Filed:

September 25, 2001

Examiner:

S. Kaushal

Patent No.:

7,041,437

Customer No.:

21559

Issued:

May 9, 2006

Title:

THERAPEUTIC AND DIAGNOSTIC TOOLS FOR IMPAIRED

GLUCOSE TOLERANCE CONDITIONS

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Attention: Certificate of Correction Branch

REQUEST FOR CERTIFICATE OF CORRECTION UNDER 37 C.F.R. § 1.323

Applicant hereby requests that a Certificate of Correction be issued in the patent identified above. The errors to be corrected are of a minor, typographical nature, occurred in good faith, and are described in detail on the enclosed PTO Form 1050.

Certificate

MAY 0 1 2007

of Correction

MAY - 2 200

Enclosed is a check for \$100.00 in payment of the fee set forth in 37 C.F.R. § 1.20(a). If there are any other charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: 23 April 2007

Karen L. Elbing, Ich

Reg. No. 35,238

Clark & Elbing LLP 101 Federal Street Boston, MA 02110

Telephone: 617-428-0200 Facsimile: 617-428-7045

PATENT NO. 7,041,437

DATED May 9, 2006

INVENTORS Ruvkun et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

On the Cover Sheet, References Cited, in OTHER PUBLICATIONS,

On Page 1, In Myers et al., replace "et al P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase." with --et al., "P-TEN, the tumor suppressor...phosphatase."--;

On Page 1, In Maehama et al., replace "et al The tumor suppressor,...3,4,5-trisphosphate." with --et al., "The tumor suppressor,...3,4,5-trisphosphate."--; On Page 1, In Khan et al., replace "et al. Obesity and insulin resistance." with --et al., "Obesity and insulin resistance."--;

On Page 1, In Lonnqvist et al., replace "et al, Overexpressin of the obese (ob) gene in adipose tisse of obese subjects." with --et al., "Overexpression of the obese (ob) gene in adipose tissue of obese subjects."--;

On Page 1, In Ogg et al., replace "et al, The C. elegans...signaling pathway." with --et al., "The C. elegans...signaling pathway."--;

On Page 1, In Fontaine et al., replace "et al Years of life lost due to obesity." with --et al., "Years of life lost due to obesity."--;

On Page 1, In Shulman, replace "Shulman Cellular mechanisms of insulin resistance." with --Shulman, "Cellular mechanisms of insulin resistance."--;

On Page 1, In Hlrosumi et al., replace "Hlrosumi et al. A central role for JNK in obesity and insulin resistance" with --Hirosumi et al., "A central role for JNK in obesity and insulin resistance."--;

On Page 2, In Dorman et al., replace "caenorhabditis elegans" with

--Caenorhabditis elegans--;

On Page 2, In Ebina et al., replace "the human...transmembrane signalling." with -- The human...transmembrane signaling.--;

On Page 2, In Green et al., replace "mulitple" with --multiple--;

MAILING ADDRESS OF SENDER:

Karen Elbing, Ph.D.


Clark & Elbing LLP

101 Federal Street

Boston, MA 02110

Customer No.: 21559

SUBSTITUTE FORM PTO 1050



PATENT NO. 7,041,437

DATED May 9, 2006

INVENTORS Ruvkun et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

On Page 2, In Klass, replace "a method for the isolation of longevity mutants" with --A method for the isolation of longevity mutants--;

On Page 3, In Li et al., replace "protein protein" with --protein--;

On Page 3, In Malone et al., replace "a screen" with -- A screen--;

On Page 3, In Nagasawa et al., replace "amino-terminal" with -- Amino-terminal--;

On Page 3, In O'Riordan et al., replace "et a.," with --et al.,--;

On Page 3, In Patterson et al., replace "signalling" with --signaling--;

On Page 3, In Ren et al., replace "homologl" with --homolog--.

Column 22, Line 16, replace "phermone" with --pheromone--.

Column 25, Line 44, replace "phermone" with --pheromone--.

Column 33, Line 60, replace "of a such a drug" with -- of such a drug--.

Column 36,

Line 35, within Table II, replace "trangenic" with --transgenic--; Line 51, within Table III, replace "F13B12 trangenic" with --F13B12 transgenic--;

Line 64, within Table IV, replace "non-trangenic" with --non-transgenic--.

Column 37,

Line 7, within Table IV, replace "Control trangenic" with --Control transgenic--; Line 20, within Table V, replace "Trangenic" with --Transgenic--; Line 46, within Table VI, replace "Control trangenic" with --Control transgenic--.

MAILING ADDRESS OF SENDER:

Karen Elbing, Ph.D. Clark & Elbing LLP 101 Federal Street Boston, MA 02110 Customer No.: 21559 PATENT NO. 7,041,437 NO. ADDITIONAL COPIES @ 50¢ PER PAGE

SUBSTITUTE FORM PTO 1050

PATENT NO. 7,041,437

DATED May 9, 2006

INVENTORS Ruvkun et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 39, Line 62, replace "dafpathway" with --daf pathway--.

Column 40, Line 29, replace "remodelling" with --remodeling--.

Column 42, Line 30, replace "phosphorlyation" with --phosphorylation--.

Column 49, Line 24, replace "downsteam" with --downstream--.

Column 54, Line 34, replace "promiscously" with --promiscuously--.

Column 62, Line 42, replace "candiate" with --candidate--.

Column 66, Line 48, replace "absense" with --absence--.

Column 67, Line 24, replace "Anatagonizes" with -- Antagonizes--.

Column 69,

Line 17, replace "thoughout" with --throughout--; Line 48, replace "artefact" with --artifact--.

Column 70, Line 41, replace "fluoresence" with --fluorescence--.

Column 71, Line 40, replace "undectectable" with --undetectable--.

Column 75, Line 19, replace "serotinergic" with --serotonergic--.

MAILING ADDRESS OF SENDER:

Karen Elbing, Ph.D.

Clark & Elbing LLP 101 Federal Street

Boston, MA 02110

Customer No.: 21559

SUBSTITUTE FORM PTO 1050

PATENT NO. 7,041,437

DATED May 9, 2006

INVENTORS Ruvkun et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 77,

Line 9, replace "labelled" with --labeled--; Line 10, replace "labelled" with --labeled--.

Column 78, Line 18, replace "explemplary" with --exemplary--.

Column 81, Line 46, replace "Oceangraphics" with --Oceanographics--.

Column 82, Line 5, replace "heterogenous" with --heterogeneous--.

Column 85, Line 38, replace "gonists" with --agonists--.

Column 89,

Line 24, replace "methylscopalamine" with --methylscopolamine--; Line 33, replace "allkaloids" with --alkaloids--.

Column 91, Line 44, replace "maintainence" with --maintenance--.

Column 92, Line 55, replace "coa" with --CoA--.

Column 102, Line 60, replace "absense" with --absence--.

Column 104, Line 51, replace "phophorylation" with --phosphorylation--.

MAILING ADDRESS OF SENDER:

Karen Elbing, Ph.D. Clark & Elbing LLP 101 Federal Street Boston, MA 02110

Customer No.: 21559

SUBSTITUTE FORM PTO 1050

PATENT NO. 7,041,437

DATED May 9, 2006

INVENTORS Ruvkun et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 109,

Line 44, replace "pedigress" with --pedigrees--. Line 67, replace "heterozyous" with --heterozygous--.

Column 114, Line 58, replace "Alternatively" with -- Alternatively--.

MAILING ADDRESS OF SENDER:

Karen Elbing, Ph.D. Clark & Elbing LLP 101 Federal Street

Boston, MA 02110

Customer No.: 21559

SUBSTITUTE FORM PTO 1050